重大事件即時報告 8-K 2026-07-31

Seer接獲兩份非約束性收購建議 CEO提每股2.45美元現金加CVR

AI 繁中摘要

Seer（納斯達克：SEER）於7月30日透過8-K文件確認，已收到兩份經修訂的「非邀約、非約束性」收購建議。事件源於公司近日接獲不同方面提出的收購意向，董事會轄下特別委員會將審視各項方案。

首份建議來自Radoff-JEC Group（由Bradley L. Radoff及Michael Torok等相關方組成），提出以每股2.55美元現金，另加一項或有價值權（CVR）收購Seer全部已發行A類普通股。第二份建議則來自Seer現任主席兼行政總裁Omid Farokhzad博士，提出以每股2.45美元現金，另加兩項獨立或有價值權收購全部股份。兩份建議均屬非約束性，最終條款仍有待磋商。

Seer表示，此前成立的董事會特別委員會將在顧問協助下，仔細審閱及考慮兩份建議，並同時評估其他可行方案，以決定最符合公司及全體股東利益的行動。公司強調，現階段股東毋須採取任何行動。

值得留意的是，Farokhzad博士身兼公司主席及CEO，其提出的收購建議構成「管理層收購」（MBO）性質，或引發企業管治關注；而Radoff-JEC Group一方則為活躍股東，兩者出價存在每股0.10美元差距。Seer股價短期或受消息影響而波動，投資者宜留意特別委員會最終決定、後續談判進展，以及會否出現競購或修訂出價。

截至新聞稿發出日，Seer尚未決定接納或拒絕任何建議，亦無法保證最終會達成任何交易。公司同時發表前瞻性陳述免責聲明，提醒實際結果可能與預期有重大差異。

展開英文正文

EX-99.1
2
ck0001726445-ex99_1.htm
EX-99.1

EX-99.1

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
No Stockholder Action Required at This Time
REDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that on July 28, 2026, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) to acquire all of the outstanding shares of Seer’s Class A common stock for $2.55 per share in cash plus a contingent value right.
On July 29, 2026, Seer received a revised, unsolicited, non-binding acquisition proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights. The full text of the letter received from Dr. Farokhzad outlining his revised proposal will be included in a Form 8-K filing made by Seer.
The previously constituted Special Committee of Seer’s Board of Directors, in consultation with its advisors, will carefully review and consider both
proposals, as well as other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and all Seer
stockholders.
No stockholder action is required at this time.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at [email protected].
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions of the Special Committee. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact: Patrick Schmidt [email protected]
Joele Frank, Wilkinson Brimmer Katcher Eric Brielmann / Joseph Sala
(212) 355-4449